Literature DB >> 12148723

Dose broadening due to target position variability during fractionated breath-held radiation therapy.

W G O'Dell1, M C Schell, D Reynolds, R Okunieff.   

Abstract

Recent advances in Stereotactic Radiosurgery/Conformal Radiotherapy have made it possible to deliver surgically precise radiation therapy to small lesions while preserving the surrounding tissue. However, because of physiologic motion, the application of conformal radiotherapy to extra-cranial tumors is, at present, geared toward slowing the progression of disease rather than obtaining a cure. At the University of Rochester, we are investigating the use of patient breath-holding to reduce respiratory-derived motion in fractional radiotherapy. The primary targeting problem then becomes the small variation in tumor location over repeated breath-holds. This paper describes the effects of residual target position uncertainty on the dose distribution observed by small extra-cranial tumors and their neighboring tissues during fractional radiation treatment using breath holding. We employ two computational methods to study these effects: numerical analysis via Monte Carlo simulation and analytical computation using three-dimensional convolution. These methods are demonstrated on a 2-arc, 10-fraction treatment plan used to treat a representative lung tumor in a human subject. In the same human subject, the variability in position of a representative lung tumor was measured over repeated end-expiration breath-holds using volumetric imaging. For the 7 x 7 x 10 mm margin used to treat this 12 mm diameter tumor and the measured target position variability, we demonstrated that the entire tumor volume was irradiated to at least 48 Gy-well above the tumoricidal threshold. The advantages, in terms of minimizing the volume of surrounding lung tissue that is radiated to high dose during treatment, of using end-expiration breath holding compared with end-inspiration breath-holding are demonstrated using representative tumor size and position variability parameters. It is hoped that these results will ultimately lead to improved, if not curative, treatment for small (5-20 mm diameter) lung, liver, and other extra-cranial lesions.

Entities:  

Mesh:

Year:  2002        PMID: 12148723     DOI: 10.1118/1.1485977

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  6 in total

1.  Evaluation of dosimetric margins in prostate IMRT treatment plans.

Authors:  J J Gordon; J V Siebers
Journal:  Med Phys       Date:  2008-02       Impact factor: 4.071

2.  Comparison of gross tumor volume of primary oesophageal cancer based on contrast-enhanced three-dimensional, four-dimensional, and cone beam computed tomography.

Authors:  Chao-Yue Hu; Jian-Bin Li; Jin-Zhi Wang; Wei Wang; Feng-Xiang Li; Yan-Luan Guo
Journal:  Oncotarget       Date:  2017-10-05

3.  A gated deep inspiration breath-hold radiation therapy technique using a linear position transducer.

Authors:  Svetlana I Denissova; Mammo H Yewondwossen; John W Andrew; Michael E Hale; Carl H Murphy; Scott R Purcell
Journal:  J Appl Clin Med Phys       Date:  2005-01-12       Impact factor: 2.102

4.  Towards a Clinical Decision Support System for External Beam Radiation Oncology Prostate Cancer Patients: Proton vs. Photon Radiotherapy? A Radiobiological Study of Robustness and Stability.

Authors:  Seán Walsh; Erik Roelofs; Peter Kuess; Yvonka van Wijk; Ben Vanneste; Andre Dekker; Philippe Lambin; Bleddyn Jones; Dietmar Georg; Frank Verhaegen
Journal:  Cancers (Basel)       Date:  2018-02-18       Impact factor: 6.639

5.  Anesthetic management of precise radiotherapy under apnea-like condition.

Authors:  Shilong Zhang; Bin Zhao; Dongji Chen; Ying Qi; Youguo Ma; Juan Ma; Wenjuan Xie; Haiyan Guo
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 6.  Normal tissue toxicity after small field hypofractionated stereotactic body radiation.

Authors:  Michael T Milano; Louis S Constine; Paul Okunieff
Journal:  Radiat Oncol       Date:  2008-10-31       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.